Docusign Envelope ID: 51C56719-7308-8037-81A4-CB40A6EBC421

Enclosure 1: Affidavit Supporting Request for Withholding from Public Disclosure (10 CFR 2.390)

I, Travis A. Chapman, Director of U.S. Regulatory Affairs & Licensing, of *new*cleo Americas LLC (newcleo), a wholly owned subsidiary of Newcleo Ltd, do hereby affirm and state:

1) I am authorized to execute this affidavit on behalf of newcleo. I am authorized to review information submitted to or discussed with the U.S. Nuclear Regulatory Commission (NRC) and apply for withholding of information from disclosure. The purpose of this affidavit is to provide the information required by 10 CFR 2.390(b) in support of this request.

2) I have knowledge of the criteria developed and used by newcleo in designating information as sensitive, proprietary, confidential, or other categories of information control within the company.

3) Pursuant to the provision of Paragraph (b)(4) of 10 CFR 2.390, the following is furnished for consideration by the NRC in determining whether the information sought to be withheld from public disclosure should be withheld:

   a) The information sought to be withheld from public disclosure in Enclosure 2 is the property of newcleo Americas LLC or another member of Newcleo Ltd. This information was developed with the explicit understanding that it would be managed as proprietary and confidential. This information has been held in confidence by newcleo.

   b) The information sought to be withheld from public disclosure in Enclosure 2 is not available to the public.

   c) The information sought to be withheld from public disclosure in Enclosure 2 is of a type that is held in confidence by newcleo through its implementing procedures with a rational basis for doing so. This information includes plans associated with commercialization of a newcleo technology for the U.S. market and associated strategies. This information is managed as proprietary and confidential with limited access to prevent impacts on newcleo's business development and commercial efforts.

   d) Enclosure 2 contains information concerning newcleo's planned activities for development and licensing of its proposed U.S. mixed oxide fuel facility, including anticipated regulatory submittals, development schedules, predecisional licensing strategies, facility-design information, and commercial planning assumptions. Public disclosure of this information could cause substantial competitive harm to newcleo by revealing nonpublic business expectations, project assumptions, development priorities, and market strategy. A competitor could use this information to inform or accelerate development of a competing facility, product, or commercial offering.

   e) The information marked as proprietary and contained in Enclosure 2 is transmitted to the NRC in confidence and under the provisions of 10 CFR 2.390. It is to be received in confidence by the NRC.

Docusign Envelope ID: 51C56719-7308-8037-81A4-CB40A6EBC421

I declare under the penalty of perjury that the foregoing is true and correct. Executed on August 3, 2026.

Yours truly,

Signed by:
801F207794FA648B...

Travis A. Chapman
Director of U.S. Regulatory Affairs & Licensing
*new*cleo Americas LLC